Elevated plasma total nitrite levels may be related to migraine attacks: Migren atakları plazma total nitrit seviyesinde yükselme ile ilişkili olabilir

Münife  Neyal; Sırma Geyik; Mustafa Çekmen; Ayşe Balat; Abdurrahman Neyal

doi:10.5455/GMJ-30-160373

Authors

Münife Neyal Department of Neurology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
Sırma Geyik Department of Neurology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
Mustafa Çekmen Department of Biochemistry, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
Ayşe Balat Department of Pediatrics, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey https://orcid.org/0000-0002-8904-1348
Abdurrahman Neyal Neurology Clinic, Dr. Ersin Arslan State Hospital, Gaziantep, Turkey

DOI:

https://doi.org/10.5455/GMJ-30-160373

Keywords:

Etiopathogenesis, migraine, nitric oxide, serum total nitrite levels

Abstract

Both vascular and neuronal mechanisms are the main foci of investigation in defining the pathophysiology of migraine attacks. This study was designed to evaluate the possible role of nitric oxide (NO) in migraine patients in the natural course of unprovoked attacks and attack-free periods. The mean plasma nitrite levels of 26 migraine patients during attacks and attack-free periods were compared within group and with those of 26 healthy controls. Plasma total nitrite levels were measured by Greiss reaction. Mean plasma total nitrite levels of migraine patients during attacks and attack-free periods and of controls were 36.5±7.5 μmol/l, 27.81±4.8 μmol/l and 25.19±4.1 μmol/l, respectively. These results demonstrated that total nitrite levels during attacks were significantly higher in migraineurs than both during attack-free periods and those of controls (P=0.001 and P=0.001, respectively). No significant difference was observed between migraineurs during attack-free periods and controls in this regard (P=0.534). Based on these results, we suggest that NO pathway may play a key role in the pathogenesis of migraine attacks.

Metrics

Metrics Loading ...

References

Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible moleculer mechanism of migraine pain. Neuroreport 1993;4(8):1027-30.

Lassen LH, Cristiansen I, Olesen J, Ashina M, Uldrich V. Nitric oxide synthase inhibition in the treatment of migrain attacks. Cephalalgia 1998;18(1):27-9.

Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 2004;110(3);675–80.

Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthse inhibitor can antagonize neurojenic and calcitonin gene-releated peptide dilation of dural meningeal vessels. Br J Pharmacol 2002;137(1):62-8.

De Alba J, Clayton NM, Collins SD, Colthup P, Chessell I, Knowles RG. GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain 2006;120(1- 2):170–81.

Headache classification subcommittee of the international headache society. The international classification of headache disorders. 2 nd edition. Cephalagia 2004;24:24-37.

Rhodes PM, Leone AM, Francis PL, Struthers AD, Moncada S. The L-arginine:nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun 1995;209(2):590-6.

Henderson DE, Mello JA. Physicochemical studies of biologically active peptides by low-temperature reversedphase high-performance liquid chromatography. J Chromatogr 1990;19(499):79-88.

Silva FA, Rueda-Clausen CF, Silva SY, Zarruk JG, Guzm|n JC, Morillo CA, et al. Endothelial function in patients with migraine during the interictal period. Headache 2007;47(1):45–51.

Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 1994;15(5):149–53.

Sances G, Tassorelli C, Pucci E, Ghiotto N, Sandrini G, Nappi G. Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia 2004;24(2):110–9.

Thomsen LL, Olesen J. A pivotal role of nitric oxide in migraine pain. Ann N Y Acad Sci 1997;19(835):363–72.

Christiansen I, Iversen HK, Olesen J. Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. Cephalalgia 2000;20(5):437–44.

Capuano A, De Corato A, Lisi L, Tringali G, Navarra P, Dello Russo C. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain 2009;5:43. https://doi.org/10.1186/1744-8069-5-43

Bagdy G, Riba P, Kecskeméti V, Chase D, Juh|sz G. Headachetype adverse effects of NO donors: vasodilation and beyond. Br J Pharmacol 2010;160(1):20-35.

Tvedskov JF, Tfelt-Hansen P, Petersen KA, Jensen LT, Olesen J. CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine. Cephalalgia 2010;30(11):1346-53.

Napoli R, Guardasole V, Zarra E, Matarazzo M, D’Anna C, Sacc{ F, et al. Vascular smooth muscle cell dysfunction in patients with migraine. Neurology 2009;72(24):2111-4.

Messlinger K, Lennerz JK, Eberhardt M, Fischer MJ. CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache 2012;52(9):1411-27.

Steinberg A, Nilsson Remahl AI. Role of nitric oxide in cluster headache. Curr Pain Headache Rep 2012;16(2):185-90.

Neyal M, Yimenicioglu F, Aydeniz A, Taskin A, Saglam S, Cekmen M, et al. Plasma nitrite levels, total antioxidant status, total oxidant status, and oxidative stress index in patients with tension-type headache and fibromyalgia. Clin Neurol Neurosurg 2013;115(6):736-40.